Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphomas in the elderly.

M V Fiorentino1

  • 1Medical Oncology Dpt, Padua General Hospital.

Leukemia
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Elderly lymphoma patients face excess mortality due to treatment fragility and lower remission rates. Tailored, less aggressive therapies and watchful waiting improve outcomes for older adults with lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

International journal of medical sciences·2005
Same author

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Clinical, pathological and therapeutic aspects of oligodendroglioma.

Cancer treatment reviews·1998
Same author

Unusual nasal and orbital involvement of glioblastoma multiforme: a case report and review of the literature.

Journal of neuro-oncology·1998
Same author

Treatment of high-grade gliomas in the elderly.

Oncology·1998
Same author

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

European journal of cancer (Oxford, England : 1990)·1997
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
See all related articles

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Hematology

Background:

  • Elderly patients with lymphoma experience significantly higher mortality rates during and after treatment.
  • Contributing factors include age-related fragility, lower remission rates due to dose intolerance, and a high incidence of secondary malignancies.
  • Treatment challenges and cure rates decline progressively with increasing age, particularly after 60.

Purpose of the Study:

  • To review and propose optimized management strategies for elderly patients diagnosed with lymphoma.
  • To highlight the need for less aggressive diagnostic and therapeutic approaches in this demographic.
  • To discuss age-appropriate treatment modifications for both Hodgkin lymphoma (HD) and non-Hodgkin lymphoma (NHL) in older adults.

Main Methods:

Related Experiment Videos

  • Review of existing literature and treatment guidelines for lymphoma in the elderly.
  • Discussion of modified treatment protocols, including reduced radiation doses and alternative chemotherapy regimens.
  • Exploration of "watch and wait" strategies for indolent lymphomas and palliative approaches for advanced disease.

    • Main Results:

    • Less aggressive staging procedures and modern imaging can replace invasive methods.
    • Modified radiation therapy (e.g., local radiation, lower doses) and adapted chemotherapy regimens (e.g., ChlVPP, NOVP, ABVD without D) are effective for HD.
    • For NHL, "watch and wait" is suitable for indolent types; oral chlorambucil or low-dose steroids for advanced low-grade NHL; and specific, shorter chemotherapy regimens (e.g., POCE, NOSTE) for high-grade NHL.

    Conclusions:

    • Age-appropriate modifications in staging and treatment are crucial for elderly lymphoma patients.
    • Palliative single-agent therapies or simple combinations can prolong survival and maintain quality of life in very elderly patients (over 80).
    • Individualized treatment plans, considering patient frailty and disease subtype, are essential for optimizing outcomes in geriatric lymphoma care.